Actively Recruiting

Phase 4
Age: 18Years +
All Genders
NCT07189377

Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors

Led by University Health Network, Toronto · Updated on 2025-11-17

20

Participants Needed

1

Research Sites

96 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The aim of the study is to show that transplantation of lungs from Hepatitis B-infected donors is safe when using EVLP with UV light inactivation plus antivirals

CONDITIONS

Official Title

Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Donor lung suitable for transplantation
  • Donor is HBV SAg positive and/or HBV NAT positive
  • Recipient is eligible and listed for lung transplant
  • Recipient is HBV NAT negative
  • Recipient provides written informed consent
  • Recipient has received at least 3 prior doses of Hepatitis B vaccine or has anti-HBs \u226510 IU/mL
  • Recipients with other co-morbid conditions are eligible if medically suitable for transplantation
Not Eligible

You will not qualify if you...

  • Donor is HIV positive
  • Donor is HTLV 1/2 positive
  • Donor has medical issues that normally exclude donation (e.g., cancer history, organ dysfunction)
  • Recipient has chronic liver disease with more than stage 2 fibrosis
  • Recipient participates in another interventional clinical trial
  • Recipient is listed for combined transplant (e.g., heart-lung, lung-liver)
  • Recipient has known allergy or contraindication to antiviral medications
  • Recipient is Hepatitis B surface antigen or Hepatitis B core antibody positive pre-transplant
  • Recipient is HIV positive
  • Recipient has low serum IgA pre-transplant

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University Health Network, Toronto General Hospital

Toronto, Ontario, Canada, M5G 2C4

Actively Recruiting

Loading map...

Research Team

A

Atul Humar, MD, FRCPC

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

PREVENTION

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here